Business Wire

WORLD-VAPERS’-ALLIANCE

Share
World Vapers’ Alliance: Back Vaping to Beat Smoking and to Save 200 Million Lives

The World Vapers’ Alliance is today launching a major global campaign – Back Vaping. Beat Smoking - with the goal of shaping international public health policies and saving 200 million lives worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006043/en/

“The weight of research and real-world evidence shows that progressive vaping policies can help millions of smokers to quit. Yet vaping remains under threat as decision-makers face pressure from anti-vaping organisations. Our campaign will make sure the evidence and the voices of vapers are heard, so that Governments will take the opportunity to save 200 million lives”, said Michael Landl, Director of the World Vapers’ Alliance.

2021 is a critical year for public health policies globally. Two major milestones will determine if Governments grab the opportunity to save 200 million lives, or decide to limit smokers’ access to life-changing quit tools. The global ‘COP9’ conference will set the direction for anti-smoking and vaping policies worldwide. And the EU’s ‘Tobacco Products Directive’ laws, currently being discussed in Brussels, will act as the benchmark for vaping policies globally.

“There is a risk that global leaders at COP 9 and at EU level - under pressure from anti-vaping activists - will introduce laws that would treat vaping the same as smoking” according to Landl. “This would spell disaster for vapers, for smokers and for public health. Millions of vapers may be forced back to smoking due to tax hikes, flavour bans, and other restrictions on vaping accessibility.”

“If they ignore that vaping is 95% less harmful than smoking and has already helped millions to quit smoking, then they will miss a golden opportunity to save lives. Nearly 200 million lives can be saved if the right vaping policies are introduced, and 2021 is an absolutely critical year if this is to be achieved,” Michael Landl added.

The World Vapers’ Alliance is launching a global campaign today to make sure that the voices of the millions of vapers who have successfully beaten smoking thanks to vaping are heard. The Back Vaping. Beat Smoking campaign will deliver a clear message to all the decision-makers around the world: The best way we can beat smoking is to promote vaping as part of public health policies.

“It’s vital that vapers' voices are heard. That’s why we’re taking our campaign out on the road, across Europe and around the world. Our campaign will combine digital and real-world activism to ensure that Governments take the opportunity to ‘Back Vaping. Beat Smoking’,” Michael Landl concluded.

ENDS

---

Notes to editor:

  • The World Vapers’ Alliance represents 23 vapers associations as well as 14.000 individual vapers from all over the world.
  • Next FCTC COP9 meeting will be held 8–13 November 2021.
  • The European Commission’s report on assessing the application of the rules laid down in the Tobacco Products Directive 2014/40/EU (TPD) was published on 20 May 2021.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 15:10:00 CEST | Press release

65 Dental Practices Demonstrate Clear ROI With a Clinician-Designed AI Workflow: Zero Missed Calls, Reduced Frontline Workload, Faster Patient Care and Measurable Returns at ScaleThe Results Build on Wildix’s Recent Launch of Wilma AI, the Embedded Agentic AI Layer Behind its Secure, Scalable UCaaS Platform Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed S

KBS Partners with Rimini Street to Accelerate its AI Vision17.9.2025 15:00:00 CEST | Press release

Korea’s public broadcasting network prioritizes funding new AI initiatives instead of costly SAP upgrades by leveraging Rimini Support™ for SAP Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Korean Broadcasting System (KBS) has partnered with Rimini Street to provide support for its SAP ECC 6.0, a strategic move that has helped to fund and accelerate its AI vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917964406/en/ KBS Partners with Rimini Street to Accelerate its AI Vision Central to KBS’s AI-enabled future is the valuable data stored in its core SAP system, a source that encompasses more than 20 years of information unique to the organization. Drawing upon this rich resource, KBS plans to create multiple AI projects and ongoing

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release

IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye